PDCD1 and neoplasm: More interestingly, they linked the long-lasting benefit of immunotherapy with anti-PD-1 antibodies in patients having renal and lung cancer with the tumor expression of a TMP–cross-reactive antigen and existence of the enterococcal prophage in feces, indicating that delivery of engineered bacterial strains with the ability to express a TMP epitope may result in more effective immunotherapy in mice [43].